Chapter 13: Pauci-immune focal and segmental necrotizing glomerulonephritis

13.2: Special patient populations 13.2.1: We recommend the addition of plasmapheresis for patients requiring dialysis or with rapidly increasing SCr. (1C) 13.2.2: We suggest the addition of plasmapheresis for patients with diffuse pulmonary hemorrhage. (2C) 13.2.3: We suggest the addition of plasmapheresis for patients with overlap syndrome of ANCA vasculitis and anti-GBM GN, according to proposed criteria and regimen for anti-GBM GN (see Chapter 14). (2D) 13.2.4: We suggest discontinuing cyclophosphamide therapy after 3 months in patients who remain dialysis-dependent and who do not have any extrarenal manifestations of disease. (2C)